Piramal Pharma Limited (IN:PPLPHARMA)
:PPLPHARMA
Total Valuation
Piramal Pharma Limited has a market cap or net worth of ₹191.28B. The enterprise value is ₹233.55B.
Market Cap₹191.28B
Enterprise Value₹233.55B
Share Statistics
Piramal Pharma Limited has 1,329,248,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,329,248,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Piramal Pharma Limited’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 1.11%.
Return on Equity (ROE)0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)1.11%
Return on Capital Employed (ROCE)0.06
Revenue Per Employee13.49M
Profits Per Employee135.63K
Employee Count6,719
Asset Turnover0.58
Inventory Turnover1.54
Valuation Ratios
The current PE Ratio of Piramal Pharma Limited is ―. Piramal Pharma Limited’s PEG ratio is 0.84.
PE Ratio―
PS Ratio3.34
PB Ratio3.72
Price to Fair Value3.72
Price to FCF132.61
Price to Operating Cash Flow20.94
PEG Ratio0.84
Income Statement
In the last 12 months, Piramal Pharma Limited had revenue of 90.61B and earned 911.30M in profits. Earnings per share was 0.69.
Revenue90.61B
Gross Profit54.89B
Operating Income6.79B
Pretax Income4.15B
Net Income911.30M
EBITDA16.49B
Earnings Per Share (EPS)0.69
Cash Flow
In the last 12 months, operating cash flow was 8.90B and capital expenditures -4.33B, giving a free cash flow of 4.57B billion.
Operating Cash Flow8.90B
Free Cash Flow4.57B
Free Cash Flow per Share3.43
Dividends & Yields
Piramal Pharma Limited pays an annual dividend of ₹0.14, resulting in a dividend yield of 0.08%
Dividend Per Share₹0.14
Dividend Yield0.08%
Payout Ratio-46.67%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.79
52-Week Price Change-30.87%
50-Day Moving Average152.49
200-Day Moving Average182.00
Relative Strength Index (RSI)44.01
Average Volume (3m)264.14K
Important Dates
Piramal Pharma Limited upcoming earnings date is May 27, 2026, During Market Hours (Confirmed).
Last Earnings DateJan 28, 2026
Next Earnings DateMay 27, 2026
Ex-Dividend Date―
Financial Position
Piramal Pharma Limited as a current ratio of 1.54, with Debt / Equity ratio of 60.08%
Current Ratio1.54
Quick Ratio0.93
Debt to Market Cap0.16
Net Debt to EBITDA2.64
Interest Coverage Ratio1.61
Taxes
In the past 12 months, Piramal Pharma Limited has paid 3.24B in taxes.
Income Tax3.24B
Effective Tax Rate0.78
Enterprise Valuation
Piramal Pharma Limited EV to EBITDA ratio is 20.97, with an EV/FCF ratio of 151.72.
EV to Sales3.82
EV to EBITDA20.97
EV to Free Cash Flow151.72
EV to Operating Cash Flow38.75
Balance Sheet
Piramal Pharma Limited has ₹7.44B in cash and marketable securities with ₹48.51B in debt, giving a net cash position of -₹41.07B billion.
Cash & Marketable Securities₹7.44B
Total Debt₹48.51B
Net Cash-₹41.07B
Net Cash Per Share-₹30.90
Tangible Book Value Per Share₹30.14
Margins
Gross margin is 51.12%, with operating margin of 7.49%, and net profit margin of 1.01%.
Gross Margin51.12%
Operating Margin7.49%
Pretax Margin4.58%
Net Profit Margin1.01%
EBITDA Margin18.20%
EBIT Margin9.19%
Analyst Forecast
The average price target for Piramal Pharma Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast2.66%
EPS Growth Forecast-153.15%